Literature DB >> 24983540

Antiretrovirals and the kidney in current clinical practice: renal pharmacokinetics, alterations of renal function and renal toxicity.

Jean C Yombi1, Anton Pozniak, Marta Boffito, Rachael Jones, Saye Khoo, Jeremy Levy, Frank A Post.   

Abstract

Assessment of renal function in HIV-positive patients is of increasing importance in the context of ageing and associated comorbidities. Exposure to nephrotoxic medications is widespread, and several commonly used antiretroviral drugs have nephrotoxic potential. Moreover, specific antiretrovirals inhibit renal tubular transporters resulting in the potential for drug-drug interactions as well as increases in serum creatinine concentrations, which affect estimates of glomerular filtration rate in the absence of changes in actual glomerular filtration rate. This review explores the effects of antiretroviral therapy on the kidney and offers an understanding of mechanisms that lead to apparent and real changes in renal function.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24983540     DOI: 10.1097/QAD.0000000000000103

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  27 in total

Review 1.  Pre-exposure Prophylaxis for HIV Infection in the Older Patient: What can be Recommended?

Authors:  Iacopo Franconi; Giovanni Guaraldi
Journal:  Drugs Aging       Date:  2018-06       Impact factor: 3.923

2.  Risk factors for kidney disease among HIV-1 positive persons in the methadone program.

Authors:  Bartłomiej Matłosz; Ewa Pietraszkiewicz; Ewa Firląg-Burkacka; Ewa Grycner; Andrzej Horban; Justyna D Kowalska
Journal:  Clin Exp Nephrol       Date:  2018-09-14       Impact factor: 2.801

3.  HIV and HCV Medications in End-Stage Renal Disease.

Authors:  Keiko I Greenberg; Mark A Perazella; Mohamed G Atta
Journal:  Semin Dial       Date:  2015-04-06       Impact factor: 3.455

Review 4.  Novel Antiretroviral Drugs in Patients with Renal Impairment: Clinical and Pharmacokinetic Considerations.

Authors:  Dario Cattaneo; Cristina Gervasoni
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-08       Impact factor: 2.441

5.  Individualized Protease Inhibitor Monotherapy: The Role of Pharmacokinetics and Pharmacogenetics in an Aged and Heavily Treated HIV-Infected Patient.

Authors:  Elena López Aspiroz; Salvador Enrique Cabrera Figueroa; María Paz Valverde Merino; Ángel Carracedo Álvarez
Journal:  Clin Drug Investig       Date:  2019-11       Impact factor: 2.859

6.  Kidney disease in the setting of HIV infection: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

Authors:  Charles R Swanepoel; Mohamed G Atta; Vivette D D'Agati; Michelle M Estrella; Agnes B Fogo; Saraladevi Naicker; Frank A Post; Nicola Wearne; Cheryl A Winkler; Michael Cheung; David C Wheeler; Wolfgang C Winkelmayer; Christina M Wyatt
Journal:  Kidney Int       Date:  2018-02-03       Impact factor: 10.612

7.  Overdose of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in an HIV-1-infected subject with attempted suicide.

Authors:  Hortensia Álvarez; Ana Mariño; Nieves Valcarce; Jesús García-González; Helena Díaz-Cambre; Josep M Llibre
Journal:  Infection       Date:  2018-08-25       Impact factor: 3.553

Review 8.  Renal effects of novel antiretroviral drugs.

Authors:  James Milburn; Rachael Jones; Jeremy B Levy
Journal:  Nephrol Dial Transplant       Date:  2017-03-01       Impact factor: 5.992

9.  Longitudinal increase in vitamin D binding protein levels after initiation of tenofovir/lamivudine/efavirenz among individuals with HIV.

Authors:  Evelyn Hsieh; Liana Fraenkel; Yang Han; Weibo Xia; Karl L Insogna; Michael T Yin; Ting Zhu; Xinqi Cheng; Taisheng Li
Journal:  AIDS       Date:  2016-07-31       Impact factor: 4.177

10.  Brief Report: APOL1 Renal Risk Variants Are Associated With Chronic Kidney Disease in Children and Youth With Perinatal HIV Infection.

Authors:  Murli U Purswani; Kunjal Patel; Cheryl A Winkler; Stephen A Spector; Rohan Hazra; George R Seage; Lynne Mofenson; Brad Karalius; Gwendolyn B Scott; Russell B Van Dyke; Jeffrey B Kopp
Journal:  J Acquir Immune Defic Syndr       Date:  2016-09-01       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.